Asthma severity and susceptibility to air pollution.
Exacerbations of asthma have been associated with exposure to ozone or particles with a 50% cut-off aerodynamic diameter of 10 microm (PM10). We postulated in this study that the association of summertime air pollution (i.e. ozone and PM10) with acute respiratory symptoms, medication use and peak expiratory flow differs among patients grouped according to asthma severity. During the summer of 1995, effects of ambient air pollution on these parameters were studied in a panel of 60 nonsmoking patients with intermittent to severe persistent asthma. These patients were recruited from our Pulmonary Out-patient Clinic. Subgroup analysis was performed on the degree of hyperresponsiveness and lung steroid use before the start of the study, as indictors for the severity of asthma. Associations of the parameters studied with ozone, PM10, nitrogen dioxide (NO2), sulphur dioxide (SO2) and black smoke were evaluated using time series analysis. Several episodes with increased summertime air pollution occurred during the 96 day study period. Eight hour average ozone concentrations exceeded the World Health Organization (WHO) Air Quality Guidelines (120 microg x m(-3)) on 16 occasions. Daily mean levels of PM10 were moderately elevated (range 16-98 microg x m(-3)). Levels of the other measured pollutants were low. There was a consistent, positive association of the prevalence of shortness of breath (maximal relative risk (RRmax) 1.18) with ozone, PM10, black smoke and NO2. In addition, bronchodilator use was associated with both ozone and PM10 levels (RRmax 1.16). Stratification by airway hyperresponsiveness and steroid use did not affect the magnitude of the observed associations. No associations with peak expiratory flow measurements were found. We conclude that the severity of asthma is not an indicator for the sensitivity to air pollution.
Hiltermann
T J
TJ
Dept of Pulmonology, Leiden University Medical Centre, The Netherlands.
Stolk
J
J
van der Zee
S C
SC
Brunekreef
B
B
de Bruijne
C R
CR
Fischer
P H
PH
Ameling
C B
CB
Sterk
P J
PJ
Hiemstra
P S
PS
van Bree
L
L
D000328:Adult; D000397:Air Pollution / Q000009:adverse effects*; D001249:Asthma / Q000188:drug therapy / Q000453:epidemiology / Q000209:etiology* / Q000503:physiopathology; D016535:Bronchial Hyperreactivity / Q000503:physiopathology; D001985:Bronchial Provocation Tests; D001993:Bronchodilator Agents / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006969:Hypersensitivity, Immediate / Q000276:immunology; D008297:Male; D009426:Netherlands / Q000453:epidemiology; D010083:Oxidants, Photochemical / Q000032:analysis; D010126:Ozone / Q000032:analysis; D010366:Peak Expiratory Flow Rate; D015995:Prevalence; D011446:Prospective Studies; D012129:Respiratory Function Tests; D012720:Severity of Illness Index
D001993:Bronchodilator Agents; D010083:Oxidants, Photochemical; D010126:Ozone